Success of Gene and Cell Therapies is dependent on efficient production of viral vectors that require optimized transfection reagents and viral vector engineering

RNA/DNA in vivo delivery is the most powerful alternative to viral vectors for nucleic acid-based therapies. They offer substantial advantages in terms of reliability,safety and costs for nucleic-acid based therapies

Broad range of solutions is needed for manufacturing of functional  proteins or antibodies at the desired scale in bacteria, yeast and mammalian cell expression systems

Optimised plasmid engineering and specific transfection reagents are key to enable protein expression in a wide range of adherent and suspension mammalian cell types